HOT StuffAll companies ↗

Medical technology

X9

X9 is developing an ultrasound-guided, power-assisted needle-insertion system for dialysis vascular access. [2] company claim

CountryUnited States

Disclosure

Your heat score

Not rated

Your personal rating, from 0 to 100.

Set your score

Saved only in this browser. Your rating is an opinion, separate from the evidence.

Components to supervised use

Schematic of documented inputs and potential delivery roles; suppliers remain unnamed.

Complete participants, relationships and sources

Imaging components

analysis

Transducer, cable and cover classes documented; vendors unknown. [4]

No transaction amount or commercial order implied.

X9 device and software

verified

Manufacturer and specification developer. [17]

No transaction amount or commercial order implied.

Future sales and support

analysis

No confirmed combined-system distribution channel. [1]

No transaction amount or commercial order implied.

User-supplied computer

verified

User supplies computer for the cleared handpiece. [4]

No transaction amount or commercial order implied.

Dialysis clinical team

verified

Qualified professionals assess access and use guidance. [4]

No transaction amount or commercial order implied.

Component dependency

analysis

Imaging components → X9 device and software

Documented component classes needed for imaging. [4]

What happens
Imaging component classes contribute to the X9 handpiece and software system.
Why it matters
The transducer and connections enable the documented imaging function.
What follows
The manufacturer integrates them; specific suppliers remain unverified.

No supplier contract established.

Future market access

analysis

X9 device and software → Future sales and support

Combined system requires further authorisation. [1] [5]

What happens
The combined system must pass the applicable market-access route.
Why it matters
Breakthrough designation does not itself permit commercial sale.
What follows
A lawful sales and support route would follow the required authorisation.

Schematic direction only; no quantity or timing.

Potential support

analysis

Future sales and support → Dialysis clinical team

Potential equipment, training and service route. [4] [1]

What happens
A future seller could provide equipment, training and support to clinical teams.
Why it matters
Teams need usable equipment and an implementation process.
What follows
No confirmed distribution agreement or combined-system order is established.

Schematic direction only; no quantity or timing.

Alignment guidance

verified

X9 device and software → Dialysis clinical team

Software indicates alignment; clinician confirms per standard care. [4]

What happens
The software indicates handpiece alignment relative to the vascular access.
Why it matters
This helps the professional interpret the handpiece-to-access relationship.
What follows
The professional still confirms the access according to standard care.

Schematic direction only; no quantity or timing.

Scope. Dependencies are not supplier contracts. No factory process, sterile design or capacity invented.

Diagram

Image, align, then assess the insertion step

X9 provides an ultrasound alignment loop; powered needle insertion is a separate investigational extension.

Use Enlarge drawing for detail. The tour caption explains the selected elements.

X9 imaging and investigational needle insertionX9 Ultrasound SystemCleared function: imaging before insertionAccess cross-sectionfistula or graftTransducer handpieceactivation button + alignment markCompatible probe coverCableAlignment indicationUser-supplied computerIllustrative interface onlyProfessional moves the probeand confirms access positionusing standard care.Guidance informs the operator; it does not replace confirmation.Investigational extensionUltrasound-guided, power-assisted needle insertionOperatorcommandPoweredinsertionStandard needleFunction described in feasibility study; drive mechanism undisclosed.Combined system is not cleared for US commercial sale.Current hardware photographs and full clinical figures unavailable.No insertion geometry, speed or automatic control is implied.

Step 1 of 3: Acquire and display alignment. Static diagram.

Guided reading, not physical motion.

Step timings allow time to read. They do not represent physical speed or duration.

  1. Acquire and display alignment

    A covered ultrasound handpiece sits on the limb over an arteriovenous fistula or graft. Its cable connects to a user-supplied computer. The software indicates alignment with the access. The handpiece has an activation button and a positioning mark.

  2. Keep the professional in control

    The operator translates and rotates the handpiece using the guidance. A qualified professional still confirms access position by standard care. FDA K251673 covers this stage before insertion and excludes paediatric use.

  3. Test powered insertion separately

    The clinical abstract describes an operator-controlled device inserting a standard dialysis needle into an arm fistula. The combined system is investigational. Its inaccessible full figures and absent current product photographs prevent a defensible mechanical cutaway.

A functional probe symbol sits above a simplified vessel. A cable leads to a computer with an illustrative alignment indication. A separate operator loop returns to the handpiece. Below a divider, the investigational sequence shows operator command, powered insertion and needle output without inventing the device mechanism.

Sources. [4] [18] [1] [16]

Limitations.

  • Functional diagram from FDA descriptions and the accessible clinical abstract. Current product photographs, full clinical figures and internal mechanical design remain unavailable. No actual housing, clinical screen, insertion angle, speed, depth, success rate or automatic control is claimed. The powered combination remains unavailable for US commercial sale.
Evidence
  • verified. The cleared X9 Ultrasound System has a transducer handpiece, cable and user-supplied computer. Software indicates alignment; the operator moves the handpiece. [4]
  • verified. Qualified professionals must confirm access position per standard care before cannulation. The cleared indication precedes needle insertion. [4]
  • company claim. The investigational combination uses ultrasound guidance and operator-controlled powered insertion of a standard dialysis needle. The accessible feasibility abstract describes this function, not its detailed mechanical construction. [18] [1]
  • analysis. The combined system has no US marketing authorisation. Current hardware imagery and the full clinical paper figures were unavailable in this audit. [16] [18] [1]

Diagram elements

  • heading: explanatory simplification. Cleared imaging system identity and functional scope PDF page 5, Device Description Summary [4] Limitation. No production enclosure or dimensions inferred.
  • tissue: explanatory simplification. Probe over a simplified access and tissue boundary PDF pages 5-6, handpiece positioned on limb and AVF/G indication [4] Limitation. Conceptual access cross-section, not patient anatomy or a clinical positioning instruction.
  • handpiece: explanatory simplification. Transducer handpiece, compatible cover, activation button and alignment mark PDF page 5, Device Description Summary [4] Limitation. Functional symbols only; no unavailable photograph or mechanical cutaway recreated.
  • computer: explanatory simplification. Cable carries imaging information to user-supplied computer and alignment indicator PDF page 5, cable, computer, software and graphical interface [4] Limitation. Interface illustration is not an actual screen or a validated diagnostic readout.
  • operator: explanatory simplification. Operator translation/rotation and standard-care confirmation PDF page 4, Indications for Use; page 5 positioning [4] Limitation. No autonomy, scan depth or placement accuracy implied.
  • insertion: explanatory simplification. Separate investigational branch: operator control, powered insertion and standard needle Accessible Methods and Objective in publisher abstract [18] Limitation. Full methods and figures inaccessible. No motor, carriage, needle mount, depth-control or feedback design inferred.
  • limitations: explanatory simplification. Commercial and evidence boundary Investigational device statement; FDA Breakthrough paragraph [1] Limitation. Designation is not clearance of combined device; current imagery remains unavailable.

Interactive 3D explainer

Imaging guidance and a disclosed mechanism

Follow the cleared imaging function, then inspect the separate mechanical embodiment published in X9’s 2025 patent.

The static explanation below is available without 3D or JavaScript.

Evidence boundary. The imaging scene is a functional schematic. The mechanical views follow patent drawings, not verified current hardware or manufacturing CAD. Powered insertion is not represented as cleared. No clinical procedure is demonstrated.

Static explanation and all component roles
  1. Imaging function: a stationary explanatory view, not measured motion.
  2. Image and alignment: a stationary explanatory view, not measured motion.
  3. Patent exterior: a stationary explanatory view, not measured motion.
  4. Disclosed drives: a stationary explanatory view, not measured motion.
  5. Disclosed controller: a stationary explanatory view, not measured motion.
Tissue context
Tissue separates the surface probe from the access beneath it.

Purpose. The surface alone cannot show the underlying structure.

A stationary illustrative section, not patient anatomy or positioning advice.

analysis | inspected 2026-11-01 | Source 1

Vascular access
The simplified tube represents the access that the imaging helps locate.

Purpose. An alignment cue needs a structure to relate to.

No depth, diameter, blood flow or safe target is inferred.

analysis | inspected 2026-11-01 | Source 1

Ultrasound transducer
The transducer supplies ultrasound information from beneath the surface.

Purpose. Guidance software needs information about the access.

The schematic handpiece is not current product geometry. The separate patent view follows its disclosed probe.

verified | inspected 2026-11-01 | Source 1 | Source 2

Compatible cover
A compatible cover surrounds the handpiece.

Purpose. It is part of the documented imaging arrangement.

No material, sterile status or preparation procedure is specified.

verified | inspected 2026-11-01 | Source 1

Imaging information
Returned ultrasound information contributes to the symbolic image section.

Purpose. The software relates the access to the handpiece.

Moving bands and image marks are explanatory, not measured acoustic fields or patient data.

analysis | inspected 2026-11-01 | Source 1 | Source 2

Computer and alignment
The connected computer displays an alignment relationship.

Purpose. The operator needs interpretable feedback.

The screen is a symbol, not a captured product interface or diagnostic result.

verified | inspected 2026-11-01 | Source 1 | Source 2

Professional confirmation
A qualified professional positions the handpiece and confirms the access.

Purpose. The cleared indication retains standard-care confirmation.

Imaging guidance does not establish autonomous insertion or clinical safety.

verified | inspected 2026-11-01 | Source 1

Disclosed housing
The published housing supports a probe clamp and a hinged arm.

Purpose. The design links imaging and mechanical geometry through a common support.

A 2025 patent embodiment, not a verified current enclosure or production dimension.

verified | inspected 2026-11-01 | Source 1

Disclosed controller
The patent connects imaging, commands and feedback to motor control.

Purpose. Commands must remain related to observations.

Board silhouettes and paths follow the disclosure, not validated circuitry or implemented safety.

verified | inspected 2026-11-01 | Source 1

Disclosed pivot drive
A body-mounted drive rotates the arm about its pivot.

Purpose. Changing arm orientation is separate from moving the holder along it.

An isolated bench mechanism. No clinical angle or trajectory is prescribed.

verified | inspected 2026-11-01 | Source 1

Disclosed linear drive
The separate arm motor turns a screw that translates the holder.

Purpose. Screw rotation and tool travel must be mechanically connected.

No motor specification, screw pitch, force or physical speed is encoded.

verified | inspected 2026-11-01 | Source 1

Needle holder
The holder carries the simplified needle with the moving carriage.

Purpose. The tool needs a defined connection to the drive.

Shown off the body. No tissue entry, clinical technique or current product claim is demonstrated.

verified | inspected 2026-11-01 | Source 1 | Source 2

verified description; analysis geometry · X9 source. Source inspection dates are listed for each component. Publication date is recorded in the dossier source list where established. Every shape is an explanatory simplification; the scene does not establish engineering performance.

Capital, customers and market direction

Money and market

Evidence checked to . Company finances and wider-market indicators are kept separate.

Funding visibility

Undisclosed

The investor portfolio confirms a relationship but discloses no instrument, ownership or cash proceeds. [F1]

Reported rounds require primary reconciliation before cash or valuation analysis.

company claim

Buyer payment context

USD 297.52

CMS set the 2027 ESRD PPS base rate at USD 297.52, effective for 2027 services. [F2]

Bundled dialysis base payment before adjustments. It is not an X9 fee; USD 12.85 reflects phosphate binders.

verified

Operator economics

14.0% margin

DaVita reported a Q3 2026 consolidated operating margin of 14.0%, versus 16.3% in Q2. [F3]

Group operating margin, not cannulation margin or X9 savings. Quarterly mix and one-off items matter.

verified

Cash and runway

Not disclosed

Not established. Current cash, committed facilities, monthly cash burn and a funded milestone plan have not been obtained.

A financing announcement is not the cash balance. No runway estimate is shown.

analysis

What the market signal means

A clinical benefit needs a purchasing case

Bundled payment makes labour, failed access and complications relevant to a buyer, but does not create a separate device reimbursement. The case needs observed workflow savings and an acceptable total cost of ownership. [F1] [F2] [F3]

No clinical benefit or cost saving is assumed from the payment rate or operator margin.

analysis

Questions that change the financial case

  • Who pays for the device and disposables, and under which procurement and reimbursement route?
  • What observed staff time, failed access or complication costs change in a controlled workflow comparison?
  • What are manufacturing, training, service, liability and regulatory costs before scale?
Financial overview sources and dates
  1. F1 Unorthodox Ventures X9 portfolio record

    Published date not stated · Accessed 2026-11-01

  2. F2 CMS final 2027 ESRD payment rule

    Published 2026-10-28 · Accessed 2026-11-01

  3. F3 DaVita Q3 2026 results

    Published 2026-10-29 · Accessed 2026-11-01

The development

On 26 October 2026, X9 announced FDA Breakthrough Device Designation and reported ten-patient ACCESS-2 findings. The combined system remains investigational. [1] company claim

Claims and evidence

  • X9 is developing an ultrasound-guided, power-assisted needle-insertion system for dialysis vascular access. [2]

    company claim

  • On 26 October 2026, X9 announced FDA Breakthrough Device Designation and reported ten-patient ACCESS-2 findings. The combined system remains investigational. [1]

    company claim

  • The FDA's October 2025 clearance record identifies X9, Inc. in Wallingford, Connecticut. [4]

    verified

  • X9 describes itself as privately held. [1]

    company claim

  • An ownership chart dated 2 April 2025 records RVM Holdings, LLC holding 17.5% of X9. Current voting control is not established. [7]

    verified

  • The paper first published on 7 April 2026 reports seven patients and eight insertion attempts: six first-attempt successes and two unsuccessful attempts in the first patient. [2]

    verified

  • The paper's abstract reports no complications during its single-centre, one-day feasibility study. This does not establish longer-term safety. [2]

    verified

  • X9 reports successful needle placement and dialysis initiation in ACCESS-2, with no device-related adverse events reported. Attempt-level results and all-cause adverse-event tables are unavailable. [1]

    company claim

  • The sponsor's ACCESS-2 registry record lists ten participants, completion on 30 April 2026 and a last posted update on 29 May. No results are posted. [3]

    verified

  • FDA clearance K251673, dated 17 October 2025, covers ultrasound imaging before needle insertion. It does not clear the combined power-assisted system. [4]

    verified

  • Breakthrough designation expedites development and review; it is not marketing authorisation or proof of efficacy. [5]

    verified

  • X9 announced its first-in-human feasibility study on 12 November 2025, before the April 2026 paper. [10] [2]

    verified

  • The registry specifies cannulation success within up to three attempts as its primary outcome; the October release describes a primary safety objective. The protocol needs reconciliation. [3] [1]

    analysis

  • The investment question is whether assisted cannulation can reduce failed attempts and total clinic cost against a matched standard-care comparator. [8] [6]

    analysis

Assessment

TopicReading and evidence
Product and mechanismThe operator aligns a handheld ultrasound-guided device before powered insertion. Human control remains central; autonomy and superiority are not demonstrated. [2]

analysis

Customers and buying processDialysis providers are the likely buyers. DaVita's original interview explains its interest, but investment and clinical interest do not establish procurement or purchasing criteria. [6]

analysis

Commercial proofNot established. Signed orders, paid deployments, revenue and customer retention records are missing.

unknown

Pricing or economicsNot established. Device and consumable prices, service costs, reimbursement treatment and costed clinic workflow comparisons are missing.

unknown

Competitors and substitutesManual and conventional ultrasound-guided cannulation are relevant substitutes. The independent cohort defines success as two needles without extra attempts; it cannot be ranked against X9's different endpoints. [8] [2] [3]

analysis

DistributionDaVita's involvement could provide clinic access. Channel exclusivity, purchasing commitments and adoption outside the investor's network remain unestablished. [6]

analysis

Intellectual property or defensibilityPublished application US20250345025A1 describes vascular-access technology and names X9 as original assignee. Publication alone establishes neither enforceable scope nor freedom to operate. [9]

analysis

Manufacturing or operational scalingNot established. Supplier qualification, production yields, capacity, service reliability, cleaning validation and training requirements for deployment are missing.

unknown

RegulationThe cleared imaging indication and investigational insertion system must remain separate. The designation letter, grant date and agreed evidence requirements for the combined system are missing. [4] [5] [1]

analysis

Capital needsEarlier financing coverage does not establish current runway. A cash balance, burn rate and costed clinical, regulatory and production plan are needed. [11]

analysis

Key risksSmall feasibility samples, selected access anatomy, endpoint inconsistency and missing comparative results limit conclusions about routine clinic benefit. [2] [3] [1]

analysis

Next falsifiable milestonePublish complete ACCESS-2 outcomes and the planned VA-ASSIST comparison with standard care. The latter registers 35 planned participants but is not yet recruiting in its 2 October 2026 update; no results are posted. [3] [12]

analysis

Ownership and identityThe historical 17.5% holding does not settle current control. The chart's broad subsidiaries heading is insufficient to classify X9 as a controlled subsidiary; obtain current voting and board agreements. [7]

analysis

Clinical generalisabilityACCESS-2 is registered as an unmasked, single-group feasibility study in Tashkent with constrained access anatomy and a one-week outcome horizon. Repeated sessions are not independent patients. [3]

analysis

Adverse events and limitationsThe accessible first-study abstract lacks a detailed adverse-event table and longer follow-up. ACCESS-2's device-related reporting cannot establish absence of all harm. Full paper access and adjudicated study data remain missing. [2] [1]

analysis

Event chronology and freshnessThe distinct October disclosure is the reported designation. Registered April completion cannot be presented as a new October trial occurrence. Prior technical history does not by itself invalidate the regulatory development. [3] [10] [1]

analysis

Opinion

Worth retaining for investigation if a controlled comparison shows reliable access and a clinic-level economic benefit. The strongest business test is repeatability in everyday use, including operators and anatomy beyond the feasibility setting.

Limits. Current independence remains provisional. Designation, minority investment and encouraging feasibility reports do not establish approval, efficacy or commercial demand. Full clinical reports, comparable outcomes and unit economics are still missing.

opinion

Commercial picture · 2026-11-01

Competition, costs and demand

X9 Inc., Wallingford: cleared pre-insertion imaging is distinct from investigational powered insertion. Commercial evidence remains bounded.

Capital, future buyers and payer

Schematic separating reported investment, prospective procurement and reimbursement.

Complete participants, relationships and sources

X9

verified

Documented manufacturer; combined system investigational. [17] [1]

No transaction amount or commercial order implied.

DaVita Venture Group

verified

Reported seed investor and Series B lead. [6]

No transaction amount or commercial order implied.

Dialysis provider

analysis

Prospective buyer and care provider. [4] [6]

No transaction amount or commercial order implied.

Medicare

verified

Pays facilities through ESRD PPS. [20]

No transaction amount or commercial order implied.

Reported investment

verified

DaVita Venture Group → X9

Interviews report investment; amount unverified. [6]

What happens
DaVita Venture Group reportedly invested in X9.
Why it matters
Capital supports development, rather than proving that a provider bought the device.
What follows
Commercial uptake still needs authorisation and purchasing decisions.

Schematic direction only; no quantity or timing.

Potential device supply

analysis

X9 → Dialysis provider

Potential sale and training, contingent on authorisation and purchase. [1] [4]

What happens
X9 could supply an authorised combined system to a dialysis provider.
Why it matters
The provider would need equipment and an acceptable clinical purchasing case.
What follows
A purchase, deployment and training agreement would still be required.

Schematic direction only; no quantity or timing.

Dialysis reimbursement

verified

Medicare → Dialysis provider

Bundled payment to facilities. [20]

What happens
Medicare pays qualifying dialysis facilities through its adjusted treatment bundle.
Why it matters
This funds covered dialysis services, not a separate established X9 charge.
What follows
The provider must assess device costs within its own economics.

Not an X9-specific payment.

Scope. Investment is not an order. Combined system is unavailable for US commercial sale.

Competition and substitutes

Compare complete cannulation workflows.

TopicEvidence and scope
Named imaging alternative

FDA identifies BD Prevue II Peripheral Vascular Access System as the X9 Ultrasound System predicate. Both use B-mode imaging and software analysis. [4]

verified

Regulatory comparison does not prove equal clinical performance or clear powered insertion. BD is not identified as an X9 supplier.

Manual access

Standard assessment and manual cannulation, with conventional ultrasound guidance where used, are substitutes. X9 proposes alignment guidance with operator-controlled powered insertion. [18] [8]

analysis

Study success definitions differ. No matched superiority or cost comparison was retrieved.

Funding

Investor interest is documented; primary financing amounts remain unresolved.

TopicEvidence and scope
Reported venture backing

December 2025 interviews reported DaVita Venture Group investment in the 2022 seed round and leadership of a later Series B. ExploraMed incubated X9. [6]

verified

Attributed reporting, not an opened investment agreement. Series B dates and amounts remain unverified by primary filing.

Investor record

Unorthodox Ventures includes X9 in its portfolio with a company quotation describing its support. [19]

company claim

No amount, instrument, valuation or percentage disclosed.

Amount and cash

Not established. Primary round proceeds, cash, valuation, burn and runway were not retrieved. The identified Form D was inaccessible.

Not established

Do not convert reported funding into cash.

Costs and unit economics

Buyer costs are available; X9 unit economics are not.

TopicEvidence and scope
Treatment OPEX context

DaVita reports US dialysis patient-care costs of USD 258.12 per treatment in 2024 and USD 273.34 in 2025. [13]

verified

Whole-treatment patient-care expense, not cannulation cost or X9 savings. Administration and depreciation are presented separately. Treatment mix and drugs affect comparisons.

Buyer CAPEX context

DaVita reports US dialysis property and equipment expenditure of USD 469.799 million in 2024 and USD 471.548 million in 2025. [13]

verified

Nominal annual USD; fleet and infrastructure totals, not X9 purchase spend, new-centre cost or startup factory budget.

Payment boundary

CMS states the 2026 ESRD PPS base rate is USD 281.71 and the final 2027 base rate is USD 297.52, effective for 2027 services. [20]

verified

Bundled base payment before adjustments, not a cannulation fee or guaranteed X9 reimbursement.

Missing economics

Not established. X9 price, consumable cost, service charges, training time, manufacturing yield and working-capital cycle were not retrieved.

Not established

No defensible payback or gross margin can be calculated.

Supply and production

Components are documented; vendors are not.

TopicEvidence and scope
Device inputs

FDA describes an ultrasound handpiece, cable to a user-supplied computer, compatible probe cover and alignment software. [4]

verified

Transducer, cable, computer and cover suppliers are undisclosed.

Manufacturer

FDA lists X9 Inc. as manufacturer and specification developer. The combined powered-insertion device remains investigational and unavailable for US commercial sale. [17] [1]

verified

Registration does not prove capacity, orders or distributor contracts.

Future route

Validated manufacture, compatible sterile consumables, distribution and training would be needed for scale. [4] [1]

analysis

Inferred roles, not confirmed vendors or a signed distribution network.

Drivers

Repeated access and scarce clinical time motivate the product.

TopicEvidence and scope
Repeated workflow

DaVita reported 28,733,980 US dialysis treatments in 2025. Cannulation is repeated for patients using fistulas or grafts. [13] [18]

analysis

Treatment total includes access modes outside the studied indication; not an X9 market-size estimate.

Labour and consistency

DaVita identifies clinical labour and supplies as major costs. X9 proposes alignment guidance without requiring visual ultrasound interpretation. [13] [18]

analysis

No measured staffing, training or complication reduction established.

Blockers

Combined-device authorisation and comparative benefit remain unresolved.

TopicEvidence and scope
Regulatory boundary

K251673 covers imaging validated dialysis access before insertion, with standard-of-care confirmation by qualified professionals; paediatric use is excluded. [4]

verified

Does not authorise powered insertion or autonomous cannulation.

Small clinical studies

The paper abstract reports seven patients and eight attempts: six first-attempt successes and two failed attempts in the first patient. ACCESS-2 enrolled ten patients. [18] [3]

verified

Full paper figures and methods inaccessible. Small uncontrolled cohorts do not prove comparative benefit or long-term safety.

Endpoint reconciliation

Registry primary outcome is success within three attempts; the October release describes a primary safety objective. [3] [1]

analysis

Protocol and full results needed; no registry results posted.

Implementation

Cleaning, workflow fit, sterile interfaces, false guidance, maintenance and access-anatomy variation need validation. [4] [3]

analysis

No quantified field reliability or production-quality dataset retrieved.

Comparative trial planned

VA-ASSIST registers a randomised crossover comparison with standard care for 35 planned participants, with three sessions per treatment condition. The record updated 2 October 2026 says not yet recruiting and estimates a December 2026 start. [12]

company claim

Sponsor plan, not enrolment achieved or trial results. No results posted; registration does not establish clinical superiority.

Demand and appetite

Testing and interest are not purchases.

TopicEvidence and scope
Clinical participation

ACCESS-2 records ten participants and completion on 30 April 2026 in Tashkent. X9 reports successful placement and dialysis initiation without device-related adverse events. [3] [1]

company claim

Sponsor metadata and assertions, not independent adjudication or paid demand.

Potential adoption

DaVita executive interviews express hope of using the device in its centres. [6]

verified

Interest is not procurement, exclusivity or an order.

Patient appetite

Not established. Original X9 willingness-to-use surveys, comparative patient-reported outcomes and an order book were not retrieved.

Not established

Clinical need and share prices are not public appetite evidence.

Patient outcomes to test

VA-ASSIST plans to compare cannulation success and insertion pain against standard care, alongside safety monitoring. [12]

company claim

Planned outcomes are not observed patient benefit, willingness to buy or public appetite.

Buyers, users and payers

Economic buyers differ from operators and patients.

TopicEvidence and scope
Buyer and operator

Dialysis providers are prospective equipment buyers; qualified healthcare professionals operate the cleared imaging system. [4] [6]

analysis

DaVita is a reported investor and interested operator, not a confirmed purchasing customer.

Payer

Medicare pays facilities through an adjusted per-treatment bundle. [20]

verified

No X9-specific reimbursement entitlement or pass-through fee established.

Seller

X9 is the documented manufacturer; a sales and service model for the combined system remains undisclosed. [17] [1]

analysis

Investigational deployment is not commercial delivery.

Public-company context · 2026-11-01

Listed companies around this market

Listed operator cost context. Reported investment and interest do not establish a purchasing customer.

A listed company's share price reflects its whole business. It does not establish demand for this startup, a supplier relationship or a private valuation.

DaVita Inc.

Industry context · analysis

October 2026 issuer results verify listing. DaVita is a dialysis operator and reported venture backer; its filed costs describe the buyer environment. [15] [13] [6]

No X9 purchase contract established. Financials are DaVita operations, not X9 accounts.

View DaVita Inc. on TradingView. External price data may be delayed or unavailable; filing evidence is shown below.

US patient-care cost per treatment

USD per treatment; administration and depreciation separately presented. Units: USD.

US patient-care cost per treatment, USD. Exact values and citations follow in the table.273.340258.1220242024-12-31: 258.12 USD273.3420252025-12-31: 273.34 USD
PeriodReported valueFiling and evidence
2024-01-01 to 2024-12-31258.12 USD2026-02-11 · verified
MD&A US dialysis operating expenses, page 57 [13]
2025-01-01 to 2025-12-31273.34 USD2026-02-11 · verified
MD&A US dialysis operating expenses, page 57 [13]

Operator context, not X9 costs, price or savings.

US dialysis property expenditure

USD thousands; US dialysis annual property and equipment expenditure. Units: USD thousand.

US dialysis property expenditure, USD thousand. Exact values and citations follow in the table.471,5480469,79920242024-12-31: 469,799 USD thousand471,54820252025-12-31: 471,548 USD thousand
PeriodReported valueFiling and evidence
2024-01-01 to 2024-12-31469,799 USD thousand2026-02-11 · verified
Note 24 segment expenditure, page F-46 [13]
2025-01-01 to 2025-12-31471,548 USD thousand2026-02-11 · verified
Note 24 segment expenditure, page F-46 [13]

Operator context, not X9 costs, price or savings.

Competitive landscape · 2026-11-01

Who else solves this?

Alternatives around ultrasound-guided needle access. X9 targets dialysis vascular access; general access imaging and diagnostic blood drawing are adjacent workflows, not equivalent indications.

Comparison lens. Mendaera is the closest robotic needle-guidance comparator here. BD and Butterfly support clinician-led access. Vitestro demonstrates automated venepuncture, but does not establish substitution for repeated dialysis fistula or graft cannulation. analysis

Direct competitor · San Mateo, USA

Mendaera Focalist

Handheld robotics and ultrasound guidance for needle-based interventions.

Difference
Shares image-guided needle placement with X9; broader vascular, nerve and organ access is not a matched dialysis study.
Maturity
The October 2026 partner announcement describes Focalist as FDA-cleared and commercially available with Butterfly integration.
Economics
Equipment, disposables, staff time and training require a matched quote; no comparable cost per successful dialysis access is reported.
Funding / ownership
Mendaera announced a closed USD 73 million Series B in September 2024. This is historical financing, not current cash.

Clearance is reported by the manufacturer partner. Dialysis-specific comparative outcomes were not established.

analysis

Sources and dates

Butterfly and Mendaera Focalist compatibility announcement (published 2026-10-01; accessed 2026-11-01) · Mendaera Series B announcement (published 2024-09-26; accessed 2026-11-01)

Established supplier · US product catalogue; availability elsewhere requires confirmation

BD SiteRite 9

Ultrasound with automated vessel measurements, needle tracking and catheter-tip support.

Difference
Supports operator-guided placement rather than X9 powered insertion. The existing clinician workflow remains a substantial adoption alternative.
Maturity
Marketed vascular-access system in the manufacturer catalogue.
Economics
Quote-based equipment and accessories; no observed price supports a cost advantage over X9.
Funding / ownership
BD supplies the product; product-level financing and current allocated capital are not disclosed here.

Catheter-tip confirmation and dialysis needle cannulation answer different procedural needs.

analysis

Sources and dates

BD SiteRite 9 product capabilities (published date not stated; accessed 2026-11-01)

Alternative approach · US product documentation

Butterfly iQ3

Handheld ultrasound with a vascular-access preset for visualising vessels, needles and catheters.

Difference
A portable imaging alternative when a trained clinician performs insertion. It is also a Focalist technology partner, not a separate robotic competitor.
Maturity
Current manufacturer specifications document the vascular-access offering.
Economics
Probe, software and support costs must be compared with staffing and outcomes; no matched procurement quote is established.
Funding / ownership
Butterfly supplies the ultrasound technology in the Focalist partnership; no product-specific financing amount is established here.

Imaging capability does not establish autonomous insertion or dialysis-specific success rates.

analysis

Sources and dates

Butterfly iQ3 vascular-access specifications (published date not stated; accessed 2026-11-01) · Butterfly and Mendaera Focalist compatibility announcement (published 2026-10-01; accessed 2026-11-01)

Alternative approach · Netherlands; European and planned US clinical deployment

Vitestro Aletta

Autonomous robotic diagnostic blood collection.

Difference
An adjacent automation benchmark for venepuncture. Diagnostic tubes and superficial veins are not dialysis needles, fistulas or repeated treatment access.
Maturity
Vitestro reports CE marking and FDA De Novo authorisation in August 2026, with phased US rollout planned.
Economics
Price, cost per draw and a dialysis-relevant economic comparison are not established in this announcement.
Funding / ownership
Vitestro is the developer; latest financing, ownership and cash were not verified in this source.

Not a demonstrated substitute for X9 dialysis access. Regulatory status is manufacturer-reported, not independently audited here.

analysis

Sources and dates

Vitestro Aletta FDA De Novo announcement (published date not stated; accessed 2026-11-01)

Coverage limits. This is a bounded primary-source comparison, not an exhaustive market census or independent performance test. Catalogue availability does not establish sales volume. Unreported prices, current cash and product-level funding remain unknown.

Sources

  1. 1
    X9 original designation and ACCESS-2 announcement

    company | Published 2026-10-26 | Accessed 2026-11-01

  2. 2
    First-in-human paper: accessible abstract and public disclosures

    paper | Published 2026-04-07 | Accessed 2026-11-01

  3. 3
    ClinicalTrials.gov NCT07548151: sponsor record, first posted 23 April

    registry | Published 2026-04-23 | Accessed 2026-11-01

  4. 4
    FDA K251673 clearance letter and indications for use

    regulator | Published 2025-10-17 | Accessed 2026-11-01

  5. 5
    FDA Breakthrough Devices Program explanation

    regulator | Published undated | Accessed 2026-11-01

  6. 6
    MedTech Dive original X9 and DaVita interviews

    independent | Published 2025-12-17 | Accessed 2026-11-01

  7. 7
    Washington DOH filing CN26-11: April 2025 ownership chart, PDF page 101

    filing | Published undated | Accessed 2026-11-01

  8. 8
    Coventry et al.: prospective cannulation cohort and endpoint definition

    paper | Published 2019-05-31 | Accessed 2026-11-01

  9. 9
    US20250345025A1: original patent disclosure reproduced by Google Patents

    patent | Published 2025-11-13 | Accessed 2026-11-01

  10. 10
    X9 original first-in-human study announcement

    company | Published 2025-11-12 | Accessed 2026-11-01

  11. 11
    Hartford Business Journal, 12 January 2026 issue, page 8

    independent | Published 2026-01-12 | Accessed 2026-11-01

  12. 12
    ClinicalTrials.gov VA-ASSIST sponsor registration, NCT07856095

    registry | Published 2026-10-02 | Accessed 2026-11-01

  13. 13
    DaVita 2025 Form 10-K

    primary source | Published 2026-02-11 | Accessed 2026-11-01

  14. 14
    SEC filing date

    primary source | Published 2026-02-11 | Accessed 2026-11-01

  15. 15
    DaVita October 2026 results

    primary source | Published 2026-10-29 | Accessed 2026-11-01

  16. 16
    X9 current homepage

    primary source | Published undated | Accessed 2026-11-01

  17. 17
    FDA X9 manufacturer listing

    primary source | Published undated | Accessed 2026-11-01

  18. 18
    Thompson et al. accessible abstract

    primary source | Published 2026-04-07 | Accessed 2026-11-01

  19. 19
    Unorthodox Ventures X9 portfolio

    primary source | Published undated | Accessed 2026-11-01

  20. 20
    CMS final 2027 dialysis payment update

    primary source | Published 2026-10-28 | Accessed 2026-11-01